Search Results
Your search for The ASCO ,The ASCO matches 21401 pages
Showing 13901 - 13950Serum DNA Methylation as Predictive Marker in Metastatic Breast Cancer
In the Translational Breast Cancer Research Consortium (TBCRC) 005 prospective biomarker study, reported in the Journal of Clinical Oncology by Kala Visvanathan, MBBS, MHS, of Johns Hopkins University, and colleagues, a cumulative methylation index was found to be predictive of progression-free...
Postinduction MRD Predicts Outcome From Transplantation in NPM1-Mutant AML
In an analysis of a French trial reported in the Journal of Clinical Oncology, Balsat et al found that postinduction minimal residual disease was predictive of outcome and benefit from allogeneic stem cell transplantation (ASCT) in patients with NPM1-mutant acute myeloid leukemia (AML). Nicolas...
Retinoic Acid and Arsenic Trioxide vs Retinoic Acid and Chemotherapy in APL
As reported in the Journal of Clinical Oncology by Platzbecker et al, the final results of the Italian-German phase III APL0406 trial indicate that the combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO [Trisenox]) is associated with better outcomes than standard ATRA plus...
Kerry and Simone Vickar Family Foundation Commits $2 Million for Levine Cancer Institute Hematologic Oncology Chair
Carolinas HealthCare System has announced a $2 million commitment from the Kerry and Simone Vickar Family Foundation in support of academic and research efforts at the Levine Cancer Institute in Charlotte, North Carolina. The funds will be designated to establish an endowed chair in their name: The ...
2017 Oncology Meetings
FEBRUARY ASCO-SITC Clinical Immuno-Oncology SymposiumFebruary 23-25 • Orlando, Florida For more information: http://immunosym.org FACTOR (Funding, Awareness, Collaboration, Trials, Osteosarcoma Research) Miami Conference 2017February 24-25 • Coral Gables, Florida For more information:...
Clinical Trials Actively Recruiting Patients With Cancer-Related Pain
Phase I Study Title: Qigong Mind-Body Exercise for Persistent Post-Surgical Pain in Breast Cancer Survivors: A Pilot Study Study Type: Phase I/interventional/single-group assignment Study Sponsor and Collaborators: Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Spaulding...
Richard M. Goldberg, MD, Named Director of West Virginia University Cancer Institute
Richard M. Goldberg, MD, an expert in gastrointestinal cancer, has been named the new Director of the West Virginia University Cancer Institute. Dr. Goldberg will be coming to West Virginia University from The Ohio State University’s Wexner Medical Center, where he currently serves as Klotz Family ...
‘Collateral Lethality’ May Offer New Therapeutic Approach to Cancers of the Pancreas, Stomach, and Colon
Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for the development of therapies for several cancers. Scientists at The University of Texas MD...
NCCN Working Group on Value Tools Presents Preliminary Findings and Recommendations
Over the past several years, the introduction of decision-making tools for patients from major cancer organizations, including ASCO and the National Comprehensive Cancer Network® (NCCN®), has been news, applauded as a step toward more patient-centered care and featured at many meetings. Next steps, ...
Telotristat Ethyl: A Novel Therapy for Carcinoid Syndrome—Not a Panacea but a Step in the Right Direction
The multihumoral manifestations of neuroendocrine tumors include diarrhea, cutaneous flushing, wheezing, and right-sided valvular heart disease.1 Serotonin, a biogenic amine and product of tryptophan metabolism,2 mediates several of these symptoms.3,4 Diarrhea is a cardinal and often disabling...
Liquid Biopsies Show Promise in Diffuse Large B-Cell Lymphoma
Technologic advances for detecting and analyzing cell-free circulating tumor DNA (ctDNA) from peripheral blood offer a precision method for monitoring diffuse large B-cell lymphoma (DLBCL). Although most patients with DLBCL are cured with initial therapy, those who are not cured have a poor...
Circulating Tumor DNA Profiling Identifies Clonal Evolution Patterns and Permits Classification of Tumor Subtypes in DLBCL
In a study reported in Science Translational Medicine, Florian Scherer, MD, David M. Kurtz, MD (Conquer Cancer Foundation Young Investigator), Aaron M. Newman, PhD, and colleagues from Stanford University found that analysis of circulating tumor DNA (ctDNA) permits identification of patterns of...
Women of Indigenous Communities Prefer Self-Screening for Cervical Cancer
Cervical cancer is a preventable disease if detected on time, but it remains one of the leading causes of cancer deaths among women in Latin America, particularly women of poor and indigenous communities. A new study by the University of Michigan published by Gottschlich et al in the Journal of...
Intentional Weight Loss in Postmenopausal Women May Be Linked to Reduced Endometrial Cancer Risk
Although many studies have linked obesity with an increased risk for endometrial cancer, information about the influence of weight loss on the cancer in postmenopausal women has been limited. Now, a study by Luo et al evaluating the association of weight change and endometrial cancer risk among...
Nearly Half of Patients Treated for Early-Stage Breast Cancer Report at Least One Severe Side Effect
Nearly half of women treated for early-stage breast cancer reported at least one side effect from their treatment that was severe or very severe, according to a new study published by Friese et al in Cancer. Although it might be expected for women undergoing chemotherapy, researchers found...
FDA Accepts Two sBLAs for Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer
On February 3, the U.S. Food and Drug Administration (FDA) accepted for review two supplemental Biologics License Applications (sBLAs) for pembrolizumab (Keytruda) in patients with locally advanced or metastatic urothelial cancer. Specifically, the application for first-line use was accepted and...
ASCO Releases Principles for Patient-Centered Health-Care Reform
ASCO has released “ASCO Principles for Patient-Centered Health-Care Reform,” seven recommendations designed to ensure access to high-quality cancer care amid the changing U.S. health-care delivery landscape. The principles aim to assist the new Congress and Administration, so, as they consider the...
Conquer Cancer Foundation Hosts Successful Scientific and Career Development Retreat
In October 2016, the Conquer Cancer Foundation of ASCO (CCF) hosted its Second Scientific and Career Development Retreat at ASCO headquarters in Alexandria, Virginia. Attendees included Career Development Award (CDA) and Young Investigator Award (YIA) recipients awarded between 2010 and 2016; ASCO ...
Tell Your Patients About PRE-ACT
The free video-based program, “PReparatory Education About Clinical Trials (PRE-ACT),” helps patients and their caregivers learn about clinical trials and address barriers to participation. Direct your patients to cancer.net/preact to learn more about this online resource. Also, visit...
Double Your Impact: Donate to the Conquer Cancer Foundation Today
If you’ve never given to the Conquer Cancer Foundation (CCF), now’s the time. An anonymous donor has generously offered to match—dollar for dollar—first-time gifts to CCF. Funds raised through the challenge will be used to support CCF’s vital work, including funding clinical and translational...
From Azerbaijan to America: An IDEA Recipient’s Experience
Cancer takes away millions of lives every year, and in low- and middle-income countries, the high cancer mortality rate can often be attributed to scarce means and a shortage of trained professionals. Hoping to contribute my best in the fight against this disease, I chose to become an oncologist in ...
ASCO Participates in Final White House Moonshot Event
On January 11, representatives from ASCO participated in the final event in the Cancer MoonshotSM “Making Health Care Better” series, which focused on community oncology, at the White House. ASCO community members attending the event, titled “Addressing the Cancer Challenge: Progress in Research,...
Growing Leadership Development Program Tasks Participants With Increasing Society Engagement
The 2016–2017 ASCO Leadership Development Program recently welcomed 16 new participants to its ranks. The Leadership Development Program is a yearlong program designed to shape future leaders by teaching them valuable leadership skills and providing them with networking and mentorship opportunities ...
Expert Point of View: Virginia Kaklamani, MD, and Melinda L. Telli, MD
Moderator of the press conference on this study, Virginia Kaklamani, MD, of the University of Texas Health Science Center at San Antonio, agreed that an improvement in response is important. “If you are a patient with symptoms, such as a cough from lung metastases, and I give you a combination...
Expert Point of View: Melinda L. Telli, MD
Melinda L. Telli, MD, Assistant Professor of Medicine at Stanford University Medical Center, Palo Alto, commented on this topic for The ASCO Post. She said the results of the two studies reinforce what has been emerging about the prognostic impact of tumor-infiltrating lymphocytes. “We have known...
ECCO 2017: Pembrolizumab Shows Activity in Mucosal Melanoma in Multiple KEYNOTE Studies
Three clinical trials of the immunotherapy pembrolizumab (Keytruda) have shown that it is active against a rare subtype of skin cancer, mucosal melanoma. The findings were presented by Butler et al at the 2017 European Cancer Congress (ECCO) (Abstract 1142). Until now, mucosal melanoma has often...
FDA Approves Nivolumab in Locally Advanced or Metastatic Bladder Cancer
On February 2, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab (Opdivo) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have...
FDA Establishes Oncology Center of Excellence, Names Richard Pazdur, MD, Director
On January 19, 2017, U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, MD, issued the following statement: Today the U.S. Food and Drug Administration is establishing the Oncology Center of Excellence and appointing Richard Pazdur, MD, as its Director. This will make oncology...
Expert Point of View: Frank A. Sinicrope, MD
Frank A. Sinicrope, MD, Professor of Medicine and Oncology at the Mayo Clinic, Rochester, Minnesota, told The ASCO Post that the regimen of irinotecan/cetuximab (Erbitux)/vemurafenib (Zelboraf) could be an important approach to treating this challenging tumor subtype. “BRAF-mutated tumors have a...
IASLC Statement on Philip Morris’ New Manifesto Highlights the Importance of Tobacco Control
On February 1, 2017, the International Association for the Study of Lung Cancer (IASLC) issued the following statement: “According to its own public reports, in 2016 Phillip Morris manufactured 800 billion cigarettes. Thus, [IASLC] views with some skepticism Philip Morris’ recent...
ECCO 2017: Melanoma Death Rates Will Fall by 2050, but Number of Deaths Will Increase
By 2050, the death rates from malignant melanoma will have decreased from their current levels, but the numbers of people dying from the disease will have increased due to the aging of populations. However, if new treatments for the deadly skin cancer prove to be effective, the numbers of deaths...
ECCO 2017: Breath Test Might Help Detect Stomach and Esophageal Cancers
A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the esophagus and stomach in a large patient trial presented by Markar et al at the 2017 European Cancer Congress (Abstract 6LBA). Together, stomach and esophageal...
ASH/AACR/AACI/ASTRO/ASPHO/Lungevity Foundation Statement on Administration's Executive Order
Today, the American Society of Hematology, the American Association for Cancer Research, the Association of American Cancer Institutes, the American Society for Radiation Oncology, the American Society of Pediatric Hematology/Oncology, and the LUNGevity Foundation issued a statement on the...
Immunotherapy 2.0 Named Advance of the Year in ASCO's Report
A growing number of patients with cancer are benefiting from research advances in immunotherapy, leading ASCO to name immunotherapy as the Society's Advance of the Year for a second year in a row. Released today, Clinical Cancer Advances 2017: ASCO's Annual Report on Progress Against Cancer...
ASCO Clinical Practice Guideline on Management of Small Renal Masses
As reported in the Journal of Clinical Oncology by Antonio Finelli, MD, of Princess Margaret Cancer Centre, Toronto, and colleagues, ASCO has released a clinical practice guideline on management of small renal masses. The guideline was derived from an expert panel literature search for and...
Arti Hurria, MD, on Senior Citizens: Living Through and Beyond Cancer
Arti Hurria, MD, of City of Hope, discusses the assessment of older patients with cancer.
Angela R. Bradbury, MD, on Genetic Information and Clinical Care
Angela R. Bradbury, MD, of the University of Pennsylvania, discusses genetic testing, tumor profiling, and the identification of those at increased risk for second cancers.
Allison Harvey, MPH, CHES, on Teaching Providers About Survivorship
Allison Harvey, MPH, CHES, of George Washington University, evaluates preliminary outcomes among primary care and oncology providers who took part in the Cancer Survivorship E-Learning Series (Abstract 78).
Shoshana M. Rosenberg, ScD, MPH, on Young Breast Cancer Survivors: Helping Them Cope
Shoshana M. Rosenberg, ScD, MPH, of the Dana-Farber Cancer Institute, talks about ways to help young women move from active treatment to survivorship, based on findings from focus groups in which patients discussed their unexpected physical and psychological experiences after surgery (Abstract 180).
Lauren P. Wallner, PhD, MPH, on Breast Cancer Survivorship Care: Patient Preferences
Lauren P. Wallner, PhD, MPH, of the University of Michigan, discusses her findings on the type of providers women prefer when it comes to handling survivorship care after breast cancer treatment and the need to clarify and discuss provider roles with patients (Abstract 99).
Sophia Kustas Smith, PhD, MSW, on Depression and Fatigue: Self-Managed in 'Reimagine'
Sophia Kustas Smith, PhD, MSW, of Duke University, discusses study findings on an online, symptom self-management curriculum, known as www.reimagine.me, employed for breast cancer survivors with chronic pain (Abstract 182).
Electra D. Paskett, PhD, on Preventing Lymphedema: Results of a CALGB Study
Electra D. Paskett, PhD, of The Ohio State University Comprehensive Cancer Center, discusses an intervention that increased knowledge of lymphedema in breast cancer, and the personal story that drove her research (Abstract 104).
Ann H. Partridge, MD, MPH, on Adolescent and Young Adult Patients: Their Survivorship Challenges
Ann H. Partridge, MD, MPH, of the Dana-Farber Cancer Institute, summarizes a session she co-chaired on the unique issues affecting adolescent and young adult patients, including their psychosocial needs and concerns that clinicians may overlook.
Dong Wook Shin, MD, DrPH, MBA, on Thyroid Cancer: Risk of Side Effects
Dong Wook Shin, MD, DrPH, MBA, of Seoul National University Cancer Hospital, discusses the risk of coronary heart disease and ischemic stroke in patients with thyroid cancer taking levothyroxine (Abstract 105).
Mohammad Abu Zaid, MD, on Testicular Cancer: Study Results on Metabolic Syndrome
Mohammad Abu Zaid, MD, of Indiana University Simon Cancer Center, discusses findings from a multicenter study of North American testicular cancer survivors, their prevalence of hypertension, risk factors for metabolic syndrome, and the need for screening and treatment (Abstract 102).
Emily S. Tonorezos, MD, on Childhood Cancer Survivors and Late-Occurring Effects
Emily S. Tonorezos, MD, of Memorial Sloan Kettering Cancer Center, discusses childhood cancer survivors and the protection from late-occurring anthracycline-related cardiotoxicity conferred by a RARG coding variant.
K. Holly Mead, PhD, on Identifying Models of Cancer Survivorship Care
K. Holly Mead, PhD, of George Washington University, discusses specialized survivorship-specific programs, which are gaining prominence, with over 40% of cancer centers in her study providing this type of care (Abstract 1).
Shawna V. Hudson, PhD, on Breast Cancer: A Quality-of-Life Program
Shawna V. Hudson, PhD, of Rutgers University, discusses a survivorship program designed to improve the quality of life for Hispanic and Latino breast cancer survivors (Abstract 183).
ECCO 2017: Some Patients With Early-Stage Breast Cancer May Benefit More From Breast-Conserving Therapy Than Mastectomy
Breast-conserving therapy (breast-conserving surgery combined with radiation therapy) may be superior to mastectomy in certain patients with breast cancer, according to results from the largest study on this topic to date, presented at the 2017 European Cancer Congress (Abstract 4LBA). Although...
ECCO 2017: Low Cause-Specific Mortality in Women Over 50 Treated for Ductal Carcinoma in Situ
Women over 50 who have been treated for ductal carcinoma in situ (DCIS) are more likely to be alive 10 years later than women in the general population, according to new research presented by Elshof et al at the 2017 European Cancer Congress (ECCO) (Abstract 173). DCIS differs from breast cancer...
